Journal of Ocular Biology, Diseases, and Informatics

, Volume 3, Issue 2, pp 53–59

CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration

  • Daisuke Imai
  • Keisuke Mori
  • Kuniko Horie-Inoue
  • Peter L. Gehlbach
  • Takuya Awata
  • Satoshi Inoue
  • Shin Yoneya
Article

DOI: 10.1007/s12177-010-9055-1

Cite this article as:
Imai, D., Mori, K., Horie-Inoue, K. et al. j ocul biol dis inform (2010) 3: 53. doi:10.1007/s12177-010-9055-1

Abstract

We determined whether there is an association between complement factor H (CFH), high-temperature requirement A-1 (HTRA1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor (PEDF) genotypes and the response to treatment with a single intravitreous injection of bevacizumab for age-related macular degeneration (AMD). Eighty-three patients with exudative AMD treated by bevacizumab injection were genotyped for three single nucleotide polymorphisms (SNPs; rs800292, rs1061170, rs1410996) in the CFH gene, a rs11200638-SNP in the HTRA1 gene, three SNPs (rs699947, rs1570360, rs2010963) in the VEGF gene, and four SNPs (rs12150053, rs12948385, rs9913583, rs1136287) in the PEDF gene using a TaqMan assay. The CT genotype (heterozygous) of CFH-rs1061170 was more frequently represented in nonresponders in vision than TT genotypes (nonrisk allele homozygous) at the time points of 1 and 3 months, while there was no CC genotype (risk allele homozygous) in our study cohort (p = 7.66 × 10−3, 7.83 × 10−3, respectively). VEGF-rs699947 was also associated with vision changes at 1 month and PEDF-rs1136287 at 3 months (p = 5.11 × 10−3, 2.05 × 10−2, respectively). These variants may be utilized for genetic biomarkers to estimate visual outcomes in the response to intravitreal bevacizumab treatment for AMD.

Keywords

Age-related macular degenerationBevacizumabComplement factor HGenetic biomarkerHigh-temperature requirement A-1Pigment epithelium-derived factorVascular endothelial growth factor

Copyright information

© Humana Press 2010

Authors and Affiliations

  • Daisuke Imai
    • 1
  • Keisuke Mori
    • 1
  • Kuniko Horie-Inoue
    • 1
    • 2
  • Peter L. Gehlbach
    • 5
  • Takuya Awata
    • 3
    • 4
  • Satoshi Inoue
    • 2
  • Shin Yoneya
    • 1
  1. 1.Department of Ophthalmology, Faculty of MedicineSaitama Medical UniversityIrumaJapan
  2. 2.Division of Gene Regulation and Signal Transduction, Research Center for Genomic MedicineSaitama Medical UniversityIrumaJapan
  3. 3.Division of Endocrinology and Diabetes, Department of MedicineSaitama Medical UniversityIrumaJapan
  4. 4.Division of RI Laboratory, Biomedical Research CenterSaitama Medical UniversityIrumaJapan
  5. 5.Department of OphthalmologyJohns Hopkins University School of MedicineBaltimoreUSA